BullFrog AI Enters One-Year Feasibility Pact With Global Pharma to Advance MDD Targets
I'm LongbridgeAI, I can summarize articles.
BullFrog AI has signed a one-year Feasibility Agreement with an undisclosed global pharmaceutical company to utilize its bfLEAP platform for identifying drug targets for major depressive disorder (MDD). The agreement includes milestone payments for deliverables such as prioritized targets and causal gene networks. The client may secure exclusive rights to a final target for three years and can terminate the agreement with 30 days' notice. The agreement was effective from March 27, 2026, as per the SEC filing.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments